Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance shows positive trends with increased annual revenue and improved EBITDA, but quarterly metrics are weak, with declining Q4 revenue and margins. Product development shows promise in high-margin areas like radiopharmaceuticals, yet the Q&A reveals uncertainties in data licensing and partnerships. The company's cautious optimism about fiscal '26 and improved cash position are positives, but lack of specific guidance and rising expenses temper enthusiasm. Overall, the mixed financials and unclear growth prospects suggest a neutral short-term stock price reaction.
Key Financial Performance
Total Revenue (Fiscal Year 2025) $57 million, a 14% increase year-over-year from $50.2 million in 2024. The increase was attributed to a combination of disciplined cost execution and revenue growth, including high-margin data revenue.
Research Services Revenue (Fiscal Year 2025) $52.3 million, up 4% year-over-year. This growth reflects the stabilization and renewed momentum in the core services business.
Data Revenue Stream (Fiscal Year 2025) $4.7 million, reflecting initial data licensing deals, which align with the company's strategic focus on high-margin data revenue.
Adjusted EBITDA (Fiscal Year 2025) $7.1 million, compared to an adjusted EBITDA loss of $3.9 million in fiscal 2024. This improvement was driven by revenue growth and disciplined cost management.
Revenue (Q4 2025) $12.1 million, compared to $14 million in Q4 2024. The decline was attributed to lower revenue on a relatively unchanged cost base.
GAAP Operating Loss (Q4 2025) $2 million, compared to a loss of $200,000 in Q4 2024. This included approximately $800,000 in noncash expenses such as stock-based compensation, depreciation, and equipment disposal charges.
Adjusted EBITDA (Q4 2025) Loss of $1.2 million, compared to a gain of $900,000 in Q4 2024. The decline was due to lower revenue and relatively stable costs.
Gross Margin (Q4 2025) 41%, down from 48% in Q4 2024. The decline reflects lower revenue on a relatively unchanged cost base.
Cost of Sales (Fiscal Year 2025) $28.3 million, a 3% decrease from $29.2 million in 2024. This decrease contributed to gross margin expansion.
Gross Margin (Fiscal Year 2025) 50%, up from 42% in 2024. The improvement was driven by high-margin data revenue and operational efficiencies.
Operating Expenses (Fiscal Year 2025) Declined by approximately $3.4 million year-over-year. R&D expenses decreased by $2.7 million, G&A expenses decreased by $1.2 million, while sales and marketing expenses increased by $500,000.
Cash Position (End of Fiscal Year 2025) $9.8 million, up from $2.6 million at the end of fiscal 2024. The increase was driven by operating cash flow and accounts receivable conversion.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Radiopharmaceutical services platform: Launched with expanded radioactive materials license, radiochemistry infrastructure, and screening of over 30 PDX models. Offers integrated radiopharmaceutical workflows including in vitro and ex vivo biodistribution studies and therapeutic efficacy testing.
Data licensing deals: Closed inaugural data licensing deal in Q3, followed by smaller transactions, validating the long-term vision and strategic direction.
Revenue growth and profitability: Achieved record revenue of $57 million in FY 2025, a 14% increase from FY 2024. Adjusted EBITDA swung to $7.1 million from a loss of $3.9 million in FY 2024.
Operational efficiencies: Improved revenue conversion and cost containment led to gross margin expansion to 50% from 42% in FY 2024. Reduced R&D and G&A expenses while increasing sales and marketing investments.
Leadership transition: CEO Ronnie Morris stepping down, with Rob Brainin taking over. Rob brings 25+ years of experience in life sciences and data-driven innovation.
Focus on big pharma relationships: Strengthened relationships with big pharma to ensure resilience through market cycles and engagement in larger multistudy programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic headwinds: Biotech and pharma R&D budgets remain constrained, which could impact revenue growth and customer spending.
Customer cancellations: Although there is a decrease in cancellations, the risk of customer cancellations still exists, which could affect bookings-to-revenue conversion rates.
Revenue decline in Q4: The fourth quarter revenue was weaker both sequentially and compared to the same quarter last year, reflecting potential volatility in revenue streams.
Gross margin decline: Gross margin for Q4 dropped to 41% from 48% in the prior year, driven by lower revenue on a relatively unchanged cost base.
Operating loss in Q4: The company recorded a GAAP operating loss of $2 million in Q4, compared to a smaller loss in the prior year, indicating financial challenges in the quarter.
Increased operating expenses: Operating expenses for Q4 rose by 7%, driven by higher sales and marketing costs, which could pressure profitability if not offset by revenue growth.
Dependence on big pharma: The company is focusing on strengthening relationships with big pharma, which are more resilient but could pose a risk if these partnerships do not materialize as expected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: The company expects sequential quarterly revenue increases and adjusted EBITDA profit in the next quarter and beyond. Revenue is projected to grow over the next few quarters, along with expanding operating margins.
Cash Flow and Capital Expenditures: The company anticipates remaining cash neutral over the next quarter, with projected cash growth in the second half of the year as revenue increases and margin improvements take hold. No significant capital expenditures are expected this year.
Data Business Growth: The company plans to expand its high-margin data business, which is expected to contribute to revenue growth and profitability.
Market Trends and Customer Behavior: The company has observed early signs of recovery in the biotech and pharma sectors, with a decrease in customer cancellations and an increase in bookings-to-revenue conversion rates. Strengthening relationships with big pharma remains a strategic focus.
Operational Efficiency: The company expects to maintain stable costs while increasing revenue, leading to improved gross margins.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the current market environment and expectations for fiscal '26?
A:The current market environment is still tight, but there are glimpses of improvement. Management feels cautiously optimistic about sustaining growth due to their niche offerings like the PDX bank and improved efficiency. They expect the next couple of quarters and the next year or two to be okay.
Q:What is the pipeline and expectations for data licensing contribution in fiscal '26?
A:The data licensing business is still early, but the pipeline is growing. Smaller licensing deals will happen sooner, while larger ones will take more time. Licensing revenue is expected to remain in the same range for the next year or so, with growth anticipated thereafter.
Q:What are the details of the new radiopharmaceutical service opportunity?
A:The radiopharmaceutical services will have higher price tags and margins of 50%-60%. This is a high-demand field with capacity constraints, and the company is well-positioned due to its PDX bank.
Q:How should capital allocation be approached to drive additional growth?
A:Most investments will focus on creating and deepening data sets, which are expected to be revenue-producing. There are no significant capital expenditures planned outside of this area.
Q:What is the status of partnered programs with Corellia AI?
A:Several programs within the Corellia portfolio are progressing, and the company is raising outside capital to fund these efforts. They are optimistic about the portfolio and the methodology used to develop first-class drugs.
Q:What is the nature of the partnership with Turbine AI and its impact on data licensing revenues?
A:Currently, the partnership involves licensing data to companies like Turbine AI without milestones or royalties. Over time, the company expects to develop deeper partnerships and potentially collaborate on drug development.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact revenue expectations for data licensing and the timeline for significant growth in this area. Additionally, while they expressed optimism about raising outside capital for Corellia AI, no concrete updates or timelines were provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Barry Miller
CEO Director
CEO rein
Champions effort
Champions role
Champions workflow
Director Gregory
Division PM
Form filing
Gregory Hewitt
Group LLC
LLC Research
Miller Chief
Morris CEO
Officer Ronnie
Omic vision
Oncology industry
Oncology privilege
PDX databank
PDX tumor
Research Division
Ronnie Morris
achievement material
afternoon Ronnie
background leader
bank characterization
biodistribution
core service
licensing deal
model
momentum
profitability
resource
service platform
set
CSBR Transcript
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Unknown3-12
The earnings call presents mixed signals: a decline in year-over-year revenue and gross margins, and increased operating expenses, are concerning. However, positive adjusted EBITDA, growth in core study revenue, and strategic investments in data and radiopharmaceuticals offer optimism. The absence of Q&A questions limits further sentiment insight. Given these mixed factors, the stock price is likely to remain stable over the next two weeks.
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Positive12-15
The earnings call highlights several positives: revenue growth, margin expansion, and a strong cash position. Gross margins improved significantly, and the company anticipates further expansion. Although operating expenses increased due to strategic investments, the funding environment is improving, and cancellations have returned to historic levels. The Q&A session revealed optimism about market recovery and strategic hires to boost the data business. Despite some uncertainties, the overall sentiment is positive, with expectations of continued growth and profitability, likely resulting in a stock price increase of 2% to 8%.
Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Unknown9-15
The earnings call reveals mixed signals: stable revenue with signs of recovery but increased costs leading to a loss. The data business shows potential growth, but management's vague responses in the Q&A about future opportunities and revenue guidance create uncertainty. Operational inefficiencies and increased expenses further complicate the outlook. Despite optimism in some areas, the lack of clear guidance and current financial strain suggest a neutral stock movement in the short term.
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Unknown7-25
The earnings call presents mixed signals. Financial performance shows positive trends with increased annual revenue and improved EBITDA, but quarterly metrics are weak, with declining Q4 revenue and margins. Product development shows promise in high-margin areas like radiopharmaceuticals, yet the Q&A reveals uncertainties in data licensing and partnerships. The company's cautious optimism about fiscal '26 and improved cash position are positives, but lack of specific guidance and rising expenses temper enthusiasm. Overall, the mixed financials and unclear growth prospects suggest a neutral short-term stock price reaction.
CSBR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
